TY - JOUR
T1 - Impact of tuberculosis disease on human gut microbiota
T2 - a systematic review
AU - Baral, Tejaswini
AU - Kurian, Shilia Jacob
AU - Thomas, Levin
AU - Udyavara Kudru, Chandrashekar
AU - Mukhopadhyay, Chiranjay
AU - Saravu, Kavitha
AU - Manu, Mohan K.
AU - Singh, Jitendra
AU - Munisamy, Murali
AU - Kumar, Amit
AU - Khandelwal, Bidita
AU - Rao, Mahadev
AU - Sekhar Miraj, Sonal
N1 - Funding Information:
This paper was not funded. The authors gratefully acknowledge the help and facilities provided by Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India. Dr. Tejaswini Baral is thankful for the Senior Research Fellowship award [No. TB-Fellowship/9/2022-ECD-I] from the Indian Council of Medical Research (ICMR), New Delhi.
Funding Information:
The authors gratefully acknowledge the help and facilities provided by Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India. Dr. Tejaswini Baral is thankful for the Senior Research Fellowship award [No. TB-Fellowship/9/2022-ECD-I] from the Indian Council of Medical Research (ICMR), New Delhi.
Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Introduction: This systematic review evaluates the gut microbiota (GM) status in tuberculosis (TB) patients compared to healthy volunteers due to the disease or its treatment. Areas covered: We conducted a systematic review of all articles published in PubMed, Web of Science, and Embase that assessed the impact of TB disease and anti-tubercular therapy (ATT) on GM from inception till January 2022 (Protocol registration number in PROSPERO: CRD42021261884). Regarding the microbial diversity indices and taxonomy, we found a significant difference in GM status between the TB and healthy control (HC) groups. We found an overabundance of Phylum Proteobacteria and depletion of some short-chain fatty acid-producing bacteria genera like Bifidobacteria, Roseburia, and Ruminococcus in the TB group. We found that ATT exacerbates the degree of dysbiosis caused by Mycobacteria tuberculosis disease. Expert opinion: The modulation of GM in TB patients in clinical practice may serve as a promising target to reverse the dysbiosis caused. Moreover, this can optimistically change the TB treatment outcome. We expect that appropriate probiotic supplementation with antimycobacterial treatment during tuberculosis disease will help stabilize the GM throughout the treatment phase and protect the GM from dysbiosis.
AB - Introduction: This systematic review evaluates the gut microbiota (GM) status in tuberculosis (TB) patients compared to healthy volunteers due to the disease or its treatment. Areas covered: We conducted a systematic review of all articles published in PubMed, Web of Science, and Embase that assessed the impact of TB disease and anti-tubercular therapy (ATT) on GM from inception till January 2022 (Protocol registration number in PROSPERO: CRD42021261884). Regarding the microbial diversity indices and taxonomy, we found a significant difference in GM status between the TB and healthy control (HC) groups. We found an overabundance of Phylum Proteobacteria and depletion of some short-chain fatty acid-producing bacteria genera like Bifidobacteria, Roseburia, and Ruminococcus in the TB group. We found that ATT exacerbates the degree of dysbiosis caused by Mycobacteria tuberculosis disease. Expert opinion: The modulation of GM in TB patients in clinical practice may serve as a promising target to reverse the dysbiosis caused. Moreover, this can optimistically change the TB treatment outcome. We expect that appropriate probiotic supplementation with antimycobacterial treatment during tuberculosis disease will help stabilize the GM throughout the treatment phase and protect the GM from dysbiosis.
UR - http://www.scopus.com/inward/record.url?scp=85145575220&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145575220&partnerID=8YFLogxK
U2 - 10.1080/14787210.2023.2162879
DO - 10.1080/14787210.2023.2162879
M3 - Review article
AN - SCOPUS:85145575220
SN - 1478-7210
VL - 21
SP - 175
EP - 188
JO - Expert Review of Anti-Infective Therapy
JF - Expert Review of Anti-Infective Therapy
IS - 2
ER -
